Skip to main content

Table 2 Comparison of Clinicopathological Variables between ypTNM group and pTNM (n = 756) after Propensity Score-matching Using the Greedy Nearest Neighbor Algorithm without Replacement (Caliper Width 0.2 × Standard Deviation of Logit Propensity Score])

From: Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis

Characteristics ypTNM (N = 378) pTNM (N = 378) P value*
Age (μ ± sd) 59.2 ± 10.5 59.3 ± 10.7 0.82
Female 97 (25.66%) 88 (23.28%) 0.45
Family history of cancer (yes) 74 (19.58%) 71 (18.78%) 0.78
BMI (μ ± sd, kg/m2) 23.5 ± 3.3 23.5 ± 3.6 0.96
ECOG    0.81
 0 249 (65.87%) 257 (67.99%)  
 1 111 (29.37%) 105 (27.78%)  
 2 18 (4.76%) 16 (4.23%)  
Tumor location    0.99
 Upper 120 (31.75%) 131 (34.66%)  
 Middle 53 (14.02%) 53 (14.02%)  
 Low 185 (48.94%) 178 (47.09%)  
 Whole 20 (5.29%) 16 (4.23%)  
Short diameter (μ ± sd, in cm) 3.1 ± 2.4 3.1 ± 2.0 0.59
Long diameter (μ ± sd, in cm) 4.5 ± 3.1 4.4 ± 2.8 0.72
Pathological type    0.97
 Adenocarcinoma 299 (79.1%) 298 (78.84%)  
 Signet ring cell carcinoma1 62 (16.4%) 64 (16.93%)  
 Mucinous adenocarcinoma2 17 (4.5%) 16 (4.23%)  
Differentiation grade    0.97
 Well 31 (8.2%) 30 (7.94%)  
 Moderate 175 (46.3%) 174 (46.03%)  
 Poor 172 (45.5%) 174 (46.03%)  
T stage    0.98
 T1 35 (9.26%) 37 (9.79%)  
 T2 65 (17.2%) 66 (17.46%)  
 T3 59 (15.61%) 55 (14.55%)  
 T4 219 (57.94%) 220 (58.2%)  
N stage    0.99
 N0 135 (35.71%) 139 (36.77%)  
 N1 78 (20.63%) 78 (20.63%)  
 N2 63 (16.67%) 58 (15.34%)  
 N3a 60 (15.87%) 61 (16.14%)  
 N3b 42 (11.11%) 42 (11.11%)  
TNM stage    0.48
 IA 25 (6.61%) 33 (8.73%)  
 IB 42 (11.11%) 48 (12.70%)  
 IIA 27 (7.14%) 28 (7.41%)  
 IIB 83 (21.96%) 63 (16.67%)  
 IIIA 63 (16.67%) 55 (14.55%)  
 IIIB 60 (15.87%) 69 (18.25%)  
 IIIC 78 (20.63%) 82 (21.69%)  
Vascular cancer embolus (yes) 234 (61.9%) 239 (63.23%) 0.71
Hospital stay (μ ± sd, in days) 14.2 ± 12.3 14.2 ± 11.8 0.39
Operative time (μ ± sd, in min) 206.5 ± 58.5 208.8 ± 58.5 0.59
Blood loss (μ ± sd, in ml) 153.6 ± 120.9 153.8 ± 153.4 0.22
Gastrectomy type    0.76
 Laparoscopic3 24 (6.35%) 22 (5.82%)  
 Open 354 (93.65%) 356 (94.18%)  
Resection range    0.85
 Total 159 (42.06%) 165 (43.65%)  
 Distal 167 (44.18%) 164 (43.39%)  
 Proximal 48 (12.7%) 43 (11.38%)  
 Thoraticabdominal joint 4 (1.06%) 6 (1.59%)  
Multi-organ excision (yes) 19 (5.03%) 23 (6.08%) 0.53
Reconstruction approach    0.77
 Billroth II 76 (20.11%) 85 (22.49%)  
 Billroth I 86 (22.75%) 73 (19.31%)  
 Roux-en-Y 115 (30.42%) 119 (31.48%)  
 Jejunal interposition 52 (13.76%) 55 (14.55%)  
 Other 49 (12.96%) 46 (12.17%)  
ASA    0.21
 1 57 (15.08%) 41 (10.85%)  
 2 254 (67.2%) 270 (71.43%)  
 3 67 (17.72%) 67 (17.72%)  
N of lymph nodes dissected (μ ± sd) 32.4 ± 11.3 31.7 ± 12.2 0.22
N of lymph nodes metastasis (μ ± sd) 5.4 ± 8.5 5.2 ± 8.0 0.68
  1. 1include adenocarcinoma with signet ring
  2. 2include adenocarcinoma with mucinous adenocarcinoma, mucinous adenocarcinoma with signet ring
  3. 3include total laparoscopic and laparoscopic-assisted gastrectomy
  4. *Mann-Whitney U test was used for all continuous variables
\